详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy

46| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Orthopedics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China. [2]Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.

出处：

DOI：

ISSN：

关键词： EphA2 Osteosarcoma Nanoplatform Surface functionalization Microvesicles Tumor targeting

摘要：

Despite advances in surgery and chemotherapy, the survival of patients with osteosarcoma (OS) has not been fundamentally improved over the last two decades. Microvesicles (MVs) have a high cargo-loading capacity and are emerging as a promising drug delivery nanoplatform. The aim of this study was to develop MVs as specifically designed vehicles to enable OS-specific targeting and efficient treatment of OS. Herein, we designed and constructed a nanoplatform (YSA-SPION-MV/MTX) consisting of methotrexate (MTX)-loaded MVs coated with surface-carboxyl Fe3O4 superparamagnetic nanoparticles (SPIONs) conjugated with ephrin alpha 2 (EphA2)-targeted peptides (YSAYPDSVPMMS, YSA). YSA-SPION-MV/MTX showed an effective targeting effect on OS cells, which was depended on the binding of the YSA peptide to EphA2. In the orthotopic OS mouse model, YSA-SPION-MV/MTX effectively delivered drugs to tumor sites with specific targeting, resulting in superior anti-tumor activity compared to MTX or MV/MTX. And YSA-SPION-MV/MTX also reduced the side effects of high-dose MTX. Taken together, this strategy opens up a new avenue for OS therapy. And we expect this MV-based therapy to serve as a promising platform for the next generation of precision cancer nanomedicines.© 2024. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

生物学

小类 | 1 区生物工程与应用微生物 2 区纳米科技

最新[2025]版：

大类 | 1 区

生物学

小类 | 1 区生物工程与应用微生物 2 区纳米科技

JCR分区：

出版当年[2022]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 NANOSCIENCE & NANOTECHNOLOGY

最新[2023]版：

Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q1 NANOSCIENCE & NANOTECHNOLOGY

影响因子： 10.6 最新[2023版] 11.4 最新五年平均 10.2 出版当年[2022版] 11.5 出版当年五年平均 9.429 出版前一年[2021版] 10.6 出版后一年[2023版]

第一作者：

第一作者单位： [1]Department of Orthopedics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Targeting regulated cell death in tumor nanomedicines [2]Targeting macrophage metabolism to enhance tumor immunotherapy [3]Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy [4]Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment [5]M11: A Tropism-Modified Oncolytic Adenovirus Arming with a Tumor-Homing Peptide for Advanced Ovarian Cancer Therapies [6]Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT [7]MiR-5195-3p functions as a tumor suppressor in prostate cancer via targeting CCNL1 [8]Correction: miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT [9]Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity [10]Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells